Home › Pancreatic Cancer › NCT05241249
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Phase II, Neoadjuvant Study of Parasympathetic Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Borderline Resectable Pancreatic Adenocarcinoma
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Pancreatic Ductal Adenocarcinoma * Plan for neoadjuvant chemotherapy * Available diagnostic tissue adequate for biomarker analysis * Ability to tolerate PO meds and comply with study procedures Exclusion Criteria: * Metastatic disease * Evidence of GI obstruction * Baseline bradycardia (HR\<55) or hypotension (systolic blood pressure\<90) * Use of acetylcholinesterase inhibitors * Medical conditions including: hyperthyroidism, active/symptomatic coronary artery disease, seizure disorder, peptic ulcer disease.
About the study
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and nab-paclitaxel. The exploratory objective will be to evaluate genomic biomarkers associated with parasympathetic stimulation in pancreatic cancer, and the ability to reduce tumor growth rate.
What is being tested
- Bethanechol (drug)
- Gemcitabine (drug)
- nab-paclitaxel (drug)
Sponsor: Susan E. Bates · Participants: 37 · Started: Feb 1, 2022
Contact the study team
- Research Nurse Navigator · Phone: 212-342-5162
Official record on ClinicalTrials.gov — NCT05241249
Locations in the U.S.
| New York | Columbia University Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.